LK
Therapeutic Areas
Pharming Group Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Joenja® (leniolisib) | Activated PI3K Delta Syndrome (APDS) | Approved |
| PH-1 (Recombinant Human C1 Esterase Inhibitor) | Primary Mitochondrial Diseases (e.g., Leigh Syndrome, MELAS) | Pivotal |
Leadership Team at Pharming Group
FC
Fabrice Chouraqui
Chief Executive Officer & Executive Director
KL
Kenneth Lynard
Chief Financial Officer
AR
Anurag Relan
Chief Medical Officer
LM
Leverne Marsh
Chief Commercial Officer
MS
Mireille Sanders
Chief Operations Officer
RV
Ruud van Outersterp
Chief Legal & Compliance Officer
DA
Dr. Alexander Breidenbach
Chief Business Officer
IB
Inés Bernal
Chief People Officer
MR
Maryana Reurings-Tsiganko
Vice President, Strategy & Operations
RP
Richard Peters
Chairman of the Board of Directors